Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Luminex Receives Second BARDA Contract for $642K to Develop Rapid SARS-CoV-2 Test

Luminex Receives Second BARDA Contract for $642K to Develop Rapid SARS-CoV-2 Test

Mar 31, 2020
|
staff reporter

NEW YORK – Luminex Corporation announced Tuesday it has received $642,450 from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to help develop the company's Aries SARS-CoV-2 Assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Slow Release of Viral Sequence

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

Journals Raise Concerns Over Data Source

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

Details From a Short Life

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

Genome Research Papers on Brain Expression, Inversion Assay, Polymorphic Yeast Centromeres

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.

Jun
04
Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

What's Popular?

In Molecular Diagnostics

  1. Guardant Health Prices $315M Public Offering

  2. Ravgen Sues Natera Over Cell-Free DNA Genetic Testing Patents

  3. Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients

  4. Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions

    Premium

  5. Fry Laboratories Plans COVID-19 NGS Diagnostic Kit Offering

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.